Mergers & Acquisitions ·
Stockholders approve merger with ST NewCo and reverse split up to 1-for-50
SNTISenti Biosciences Holdings, Inc.
Senti Biosciences Holdings stockholders approved the Agreement and Plan of Merger with ST NewCo Limited, enabling the acquisition. The vote also authorized a reverse stock split ranging from 1-for-20 to 1-for-50 at the Board's discretion and permitted share issuance exceeding 19.99% upon conversion of Senior Secured Convertible Notes. Three directors were elected and KPMG was reappointed as auditor. Senti Biosciences Holdings operates in the biotechnology sector, focusing on synthetic biology and gene editing technologies.